Siemens Healthineers Get FDA Nod for New SPECT/CT Scanner
The newly FDA-cleared Symbia Pro.specta SPECT/CT Scanner, which reportedly offers a variety of enhanced capabilities including low-dose CT up to 64 slices and intuitive workflow guides, was launched at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting.
The Food and Drug Administration (FDA) has granted 510(k) clearance to the Symbia Pro.specta™ SPECT/CT Scanner, according to Siemens Healthineers, the manufacturer of the device.
Launching the device at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting, Siemens Healthineers said the single-photon emission computed tomography/computed tomography (SPECT/CT) system offers advanced imaging technology. Key benefits include automated SPECT motion correction and the ability to obtain up to 64 slices of low-dose CT to facilitate detailed image quality, according to the company.
In addition to optimal low-dose imaging, Siemens Healthineers noted the Symbia Pro.specta™ SPECT/CT Scanner offers myExam Companion, which provides automated workflow guidance. The company adds that clinicians will also have access to the device’s customized clinical tools designed to ensure optimal imaging with cardiology, neurology, oncology, and orthopedic applications.
Siemens Healthineers noted the Symbia Pro.specta™ SPECT/CT Scanner will offer improved accessibility, noting that it should fit in most existing SPECT rooms and is designed to replace the Symbia Intevo™ line of SPECT/CT scanners.
“Siemens Healthineers is proud to introduce the Symbia Pro.specta SPECT/CT scanner, which provides our customers with the ideal vehicle for transitioning from their SPECT-only and first-generation SPECT/CT cameras to a state-of-the-art SPECT/CT scanner that can perform a full spectrum of nuclear medicine examinations,” said Jim Williams, Ph.D., the head of Siemens Healthineers Molecular Imaging. “The Symbia Pro.specta will help health-care institutions overcome barriers to care by ensuring accessibility through its ease of use and ability to fit into existing SPECT rooms.”
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
